Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 16 to 30 of 40 results for bph

  1. iTind for lower urinary tract symptoms caused by benign prostatic hyperplasia (MIB306)

    NICE has developed a medtech innovation briefing (MIB) on iTind for lower urinary tract symptoms caused by benign prostatic hyperplasia .

    Medtech innovation briefing
    Published
    21 September 2022

  2. Memokath-028, 044 and 045 stents for urethral obstruction (MIB123)

    NICE has developed a medtech innovation briefing (MIB) on Memokath-028, 044 and 045 stents for urethral obstruction .

    Medtech innovation briefing
    Published
    2 October 2017

  3. PLASMA system with button electrode for electrovaporisation of the prostate (MIB274)

    NICE has developed a medtech innovation briefing (MIB) on PLASMA system with button electrode for electrovaporisation of the prostate .

    Medtech innovation briefing
    Published
    31 August 2021

  4. The PLASMA system for transurethral resection and haemostasis of the prostate (HTG563)

    Evidence-based recommendations on the PLASMA system for transurethral resection and haemostasis of the prostate.

    HealthTech guidance
    Published
    6 January 2021
    View recommendations

    Sections for HTG563

  5. Evidence on the safety and efficacy of prostatic urethral temporary implant insertion for lower urinary tract symptoms caused by benign prostatic hyperplasia is limited in quantity and quality. Therefore, this procedure should only be used with special arrangements for clinical governance, consent, and audit or research. Find out what special arrangements mean on the NICE interventional procedures guidance page.

    implant insertion for lower urinary tract symptoms caused by benign prostatic hyperplasia is limited in quantity and quality. Therefore,...

    Research recommendation
    Published
    30 September 2022

  6. NICE encourages further research and publication of results from consecutive case series of patients having this procedure. Details of patient selection should be clearly documented. Reported outcomes should include the effects of the procedure on symptoms and quality of life, the duration of benefits, and the need for further procedures. All complications should be reported. NICE may review this procedure in the light of longer-term outcomes.

    lift implants to treat lower urinary tract symptoms secondary to benign prostatic hyperplasia is adequate to support the use of this...

    Research recommendation
    Published
    9 June 2015

  7. Further research, ideally in the form of randomised controlled trials, on the safety and efficacy of prostatic urethral temporary implant insertion for lower urinary tract symptoms caused by benign prostatic hyperplasia should report details of patient selection (including prostate size and the amount of median lobe enlargement), improvement in lower urinary tract symptoms in the short term and long term, re-intervention rates, and outcome measures of sexual function using established methods.

    implant insertion for lower urinary tract symptoms caused by benign prostatic hyperplasia Number IPG641 Date issued January 2019

    Research recommendation
    Published
    18 February 2019

  8. Prioritisation board decisions 2024

    Our centralised approach to prioritising guidance topics ensures that we produce guidance that is relevant, timely, accessible, and has demonstrable impact.

  9. trublood-prostate for triaging and diagnosing people with prostate cancer symptoms (MIB268)

    NICE has developed a medtech innovation briefing (MIB) on trublood-prostate for triaging and diagnosing people with prostate cancer symptoms .

    Medtech innovation briefing
    Published
    13 July 2021

  10. Rezum for treating benign prostatic hyperplasia (MIB158)

    This advice has been updated and replaced by NICE medical technologies guidance 49. 

    Withdrawn advice

  11. Prostate artery embolisation for benign prostatic hyperplasia (IPG453)

    This guidance has been updated and replaced by NICE interventional procedures guidance 611.

    Withdrawn guidance

  12. GreenLight XPS for treating benign prostatic hyperplasia (MTG74)

    We have moved Medical technologies guidance 74 to become HealthTech guidance 650. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  13. GreenLight XPS for treating benign prostatic hyperplasia (MTG29)

    This guidance has been updated and replaced by NICE healthtech guidance 650.

    Withdrawn guidance

  14. UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia (MTG58)

    We have moved Medical technologies guidance 58 to become HealthTech guidance 578. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  15. UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia (MTG26)

    This guidance has been updated and replaced by NICE healthtech guidance 578.

    Withdrawn guidance